Repligen | RGEN - Selling And Administration Expenses


Repligen reported $76.62M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Agilent USD 465M 11M Mar/2026
Align Technology USD 462.67M 2.67M Jun/2026
Bio Techne USD 109.34M 4.35M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Bruker USD 242.1M 5.1M Mar/2026
Charles River Laboratories USD 159.42M 36.71M Mar/2026
Danaher USD 2.07B 212M Jun/2026
Dentsply International USD 351M 32M Mar/2026
General Electric Aerospace USD 1.13B 47M Jun/2026
Henry Schein USD 809M 1000K Mar/2026
Illumina USD 273M 1000K Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Mettler Toledo International USD 263.33M 5.01M Jun/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
OraSure Technologies USD 13.21M 3.29M Dec/2025
Pacific Biosciences Of California USD 37.24M 25.68M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
Repligen USD 76.62M 82K Jun/2026
Revvity USD 253.88M 2.15M Mar/2026
Standard Biotools USD 18.61M 2.94M Mar/2026
Thermo Fisher Scientific USD 1.91B 111M Jun/2026
Waters USD 394M 153.99M Mar/2026
West Pharmaceutical Services USD 117.6M 18.1M Jun/2026